Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

Saved in:

Bibliographic Details
Main Authors:	Regina Berkovich, Jonathan Calkwood, Heidi Crayton, April Erwin, Simon Faissner, Ralf Gold, Joshua Katz, Mark Leekoff
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	anti-CD20 B-cell depletion disability magnetic resonance imaging multiple sclerosis ocrelizumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1609054/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
by: Regina Berkovich, et al.
Published: (2025-04-01)

Correction: B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry
by: Gregg J. Silverman, et al.
Published: (2025-07-01)

B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry
by: Gregg J. Silverman, et al.
Published: (2025-06-01)

Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab
by: Carolina Ricci, et al.
Published: (2025-06-01)

Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis
by: Alice G. Willison, et al.
Published: (2025-04-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-12-01)

Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab
by: Jelena Drulovic, et al.
Published: (2025-04-01)

Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study
by: Elena Barbuti, et al.
Published: (2025-03-01)

Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01)

Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab
by: Franz Felix Konen, et al.
Published: (2025-08-01)

Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review
by: John L. Petrie, et al.
Published: (2024-10-01)

Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
by: Bruna De Felice, et al.
Published: (2025-08-01)

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
by: Mathias Buttmann, et al.
Published: (2025-05-01)

Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry
by: Stefan Braune, et al.
Published: (2025-06-01)

Case Report: Neurofilament light chain in the follow up of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with ocrelizumab
by: Raquel Piñar-Morales, et al.
Published: (2025-04-01)

B-Cell-Depleting Immune Therapies as Potential New Treatment Options for Systemic Sclerosis
by: Gerhard Zugmaier, et al.
Published: (2025-01-01)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database
by: Xiwen Zhang, et al.
Published: (2025-07-01)

CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01)

Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge
by: Seki M, et al.
Published: (2024-11-01)

COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
by: Rahul H. Dave, et al.
Published: (2024-10-01)

Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series
by: Orhan Efe, et al.
Published: (2025-05-01)

America's water: Agricultural water demands and the response of groundwater
by: M. Ho, et al.
Published: (2016-07-01)

An open toss problem
by: Prem N. Bajaj, et al.
Published: (1993-01-01)

Corrigendum: Nitrous oxide production and consumption by marine ammonia-oxidizing archaea under oxygen depletion
by: Elisa Hernández-Magaña, et al.
Published: (2024-10-01)

Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy
by: Yuriko Sueda, et al.
Published: (2024-01-01)

Armor Piercing Projectiles Based on Depleted Uranium and the Consequences of Their Use for the Environment and People
by: M. V. Supotnitskiy
Published: (2023-08-01)

Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis
by: Wioletta Katarzyna Żukowicz-Wyrwa, et al.
Published: (2025-08-01)

Exploring the relationship between temperament traits, psychological symptoms, and functional disability assessed with the WHODAS 2.0 in persons with multiple sclerosis
by: Carmenrita Infortuna, et al.
Published: (2025-08-01)

Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
by: A. L. Maslyanskiy, et al.
Published: (2025-06-01)

Depletion-restitution therapy for autoimmune rheumatic diseases. Part 1. Fundamental prerequisites and efficacy of modern treatment technologies: anti-B-cell drugs and CAR-T therapy
by: A. M. Lila, et al.
Published: (2025-04-01)

CALCULATION UNCERTAINTIES IN SPENT FUEL INVENTORY DETERMINATION
by: Tomas Czakoj, et al.
Published: (2018-05-01)

Ozone Depletion Modulated by Arctic Polar Stratospheric Cloud Types
by: Jiahao Zhang, et al.
Published: (2025-02-01)

Process and Validation of Depletion Database Based on Evaluated Nuclear Data Libraries
by: LUO Hao, LI Jie, HUANG Shanfang, WANG Kan
Published: (2024-07-01)

Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy
by: Awada Z, et al.
Published: (2024-12-01)

Moments, Exponential Sums, and Monodromy Groups
by: Nicholas M. Katz, et al.
Published: (2025-01-01)

Impact of Age on Switching or Stopping Disease Modifying Therapies in Multiple Sclerosis
by: Areeba Siddiqui, et al.
Published: (2025-07-01)

Root aerenchyma – formation and function
by: Urška VIDEMŠEK, et al.
Published: (2006-09-01)

Implication of depleted uranium in human carcinogenesis with a glance to implementation of novel and reliable experimental models
by: Stefano Burgio, et al.
Published: (2024-12-01)